Latest Pharmacy News: Hikma making Gilead's Covid-19 drug to increase supply

Henrietta Strickland
August 9, 2020

() - Hikma Pharmaceuticals (OTC:) has started manufacturing remdesivir, an approved treatment for COVID-19 from US -based Gilead (NASDAQ:), for an undisclosed amount at its facility in Portugal, the British company's chief executive officer said. Pfizer will start ramping up that production even further through contract manufacturing services at its McPherson, Kansas, facility.

Gilead is aiming to make enough of the drug by the end of the year to treat more than 2 million COVID-19 patients, and agreed to send almost all of its remdesivir supply to the United States through September.

While we know that the development of a vaccine for the Coronavirus is in full swing with many companies fighting for the race to release the first one in market, we have seen that there is one medicine in the meantime that is working very well.

Gilead has said it aiming to supply enough remdesiver - an antiviral drug - by the end of 2020 to treat more than 2 million COVID-19 patients with plans in place to produce "several million more" doses in 2021.

Gilead said on Thursday that its manufacturing network for the drug had grown to more than 40 companies in North America, Europe and Asia.

On Friday, Pfizer said it had signed a multi-year deal with Gilead to manufacture and supply remdesivir. COVID-19 has killed over 700,000 people worldwide. State attorneys general have sought to enforce a federal patent law that would force Gilead to increase the supply of the drug and lower its price; the partnership with Pfizer will hopefully provide Gilead the bandwidth to do that.

While there are no approved drugs yet to treat COVID-19, the Food and Drug Administration granted Gilead emergency authorization in May to use remdesivir in hospitalized coronavirus patients.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER